Clinical trials: Vascular Disease
Chronic Coronary Syndrome, Coronary Artery Disease
Feasibility of a Deep Learning-based Algorithm for Non-invasive Assessment of Vulnerable Coronary Plaque
The primary objective of this study is to assess the accuracy in terms of sensitivity, specificity, negative and positive predicted values of the DL-based algorithm with respect to correct identification of the plaque and…
- Conditions
- Chronic Coronary Syndrome, Coronary Artery Disease, Stable Angina, Acute Coronary Syndrome
- Trial name
- FOCUS DL (NCT06186336)
- Testing
- Deep Learning-based Vulnerable Plaque Detection and Assessment Tool
- Where
- Italy
- Volunteers
- 200 people
- Sponsor
- GE Healthcare
Hypertension
Post-marketing Surveillance for Hypertensive Patients With Diabetes and/or Chronic Kidney Disease
This study is a post-marketing surveillance in Japan, and it is a local prospective, company sponsored and observational study of patient who have been treated by Adalat CR for hypertension with diabetes and/or chronic kidney…
- Trial name
- NCT01363336
- Testing
- Nifedipine (Adalat CR, BAYA1040)
- Where
- Japan
- Volunteers
- 1,882 people
- Sponsor
- Bayer
Multiple Myeloma
A Companion Study for Studies THAL-MM-003, CC-5013-MM-009, and CC-5013-MM-010 for Subjects With Multiple Myeloma
The study evaluated the safety of Lenalidomide monotherapy in participants with advanced multiple myeloma who had discontinued treatment with combination thalidomide plus high-dose dexamethasone or high-dose dexamethasone alone…
- Trial name
- NCT00622336
- Testing
- CC-5013, Lenalidomide
- Where
- 7 sites in Russia, Ukraine
- Volunteers
- 330 people
- Sponsor
- Celgene
Multiple Myeloma
PRospective Multiple Myeloma Impact Study
This will be a prospective, case-only, study to measure the impact of MMprofiler on treatment intention decisions in Multiple Myeloma patients.
- Trial name
- PROMMIS (NCT02911571)
- Testing
- MMprofiler SKY92 gene signature
- Where
- 9 sites in United States
- Volunteers
- 250 people
- Sponsor
- SkylineDx
Coronary Artery Disease
Non-invasive Point-of-care Diagnosis Using Machine Learning and Signal Analytics to Transform Early Detection of Heart Disease
This study is designed as a repository study to collect resting cardiac phase signals and subject meta data from eligible subjects using the Phase Signal Recorder (PSR) prior to coronary angiography.
- Trial name
- IDENTIFY (NCT03864081)
- Testing
- Phase Signal Recorder
- Where
- United States
- Volunteers
- 2,500 people
- Sponsor
- Analytics For Life
Hypertension, Diabetes
Efficacy and Safety of Azilsartan Medoxomil Used in Combination With Metformin in Participants With Hypertension and Diabetes
The purpose of this study was to evaluate the antihypertensive and antiglycemic effects, as well as the safety and tolerability of TAK-491 (azilsartan medoxomil), once daily (QD), in stage 1 hypertensive, type 2 diabetes mellitus…
- Trial name
- NCT01496430
- Testing
- Azilsartan medoxomil
- Where
- 68 sites in United States
- Volunteers
- 105 people
- Sponsor
- Takeda
Hypertension
Using Telmisartan Alone or Combination of Telmisartan -HCTZ in the Treatment of Mild to Moderate Essential Hypertension
The aim of this therapeutic observation is to demonstrate the efficacy and safety of telmisartan or telmisartan and HCTZ in the treatment of patients with mild-to-moderate essential hypertension under normal conditions of use…
- Trial name
- NCT00638911
- Volunteers
- 33,247 people
- Sponsor
- Boehringer Ingelheim
Peripheral Artery Disease, Peripheral Vascular Disease
Investigational Device Exemption Study to Determine the Safety and Efficacy of the Astron and Pulsar Stents
The objective of this study is to separately demonstrate the safety and efficacy of BIOTRONIK's Astron and Pulsar stents. The Pulsar stent will be used for the treatment of femoro-popliteal lesions, located in the native…
- Trial name
- BIOFLEX-I (NCT01319812)
- Testing
- Astron Stents, Pulsar Stents
- Where
- 35 sites in United States, Canada
- Volunteers
- 463 people
- Sponsor
- Biotronik, Inc.
Hypertension
OBPM_COYOTE2024 Physiological Data Recording With the Calibration-free Optical Aktiia G2C Device at Fingertip and Wrist, Alongside the Aktiia Oscillometric Cuff
The present study, OBPM_COYOTE2024, with N = 255 participants minimum over 1 visit (lasting ~15min), has been designed to collect raw optical data with Aktiia.product-G2C Clinical investigational device together with Aktiia G2…
- Trial name
- COYOTE2024 (NCT06698536)
- Testing
- Aktiia G2C
- Where
- Switzerland
- Volunteers
- 255 people, healthy volunteers welcome
- Sponsor
- Aktiia SA
Hypertension, Ischemic Heart Disease
Vibrometer Based Pulse Wave Analysis for Arterial Stiffness and Ischemic Heart Disease Risk Assessment
This clinical investigation will evaluate a novel contactless technology for assessing arterial stiffness and explore its potential in assessment of risk for and development of cardiovascular disease.
- Conditions
- Hypertension, Ischemic Heart Disease, Valvular Heart Disease, Heart Failure
- Trial name
- NCT06984211
- Where
- 3 sites in Sweden
- Volunteers
- 8,000 people, healthy volunteers welcome
- Sponsor
- HJN Sverige AB/Neko Health
Pulmonary Embolism
Crux Biomedical Vena Cava Filter Study - United States
The purpose of this study is to determine if the Crux Vena Cava Filter System is safe and effective in preventing pulmonary embolism.
- Trial name
- RETRIEVE 2 (NCT01120509)
- Testing
- Inferior Vena Cava Filter
- Where
- 17 sites in United States
- Volunteers
- 88 people
- Sponsor
- Crux Biomedical
Chronic Spontaneous Urticaria (CSU), Chronic Idiopathic Urticaria
A Study to Assess the Efficacy and Safety of THB335 in Adults With Chronic Spontaneous Urticaria (CSU)
THB335-201 is a Phase 2, randomized, double-blind, placebo-controlled, parallel-group, multicenter study in adults with CSU who remain symptomatic despite standard-of-care treatment.
- Trial name
- NCT07766499
- Testing
- THB335 Lower Dose, THB335 Higher Dose
- Volunteers
- 81 people
- Sponsor
- Calixis Inc.
Venous Thromboembolism
Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Total Hip Replacement Surgery
The primary objective was to compare the efficacy of once daily [q.d.] subcutaneous [s.c.] injections of Semuloparin sodium (AVE5026) with q.d. s.c.
- Trial name
- SAVE-HIP1 (NCT00697099)
- Testing
- Semuloparin sodium, Enoxaparin sodium
- Where
- 30 sites in United States, Argentina and 28 more
- Volunteers
- 2,326 people
- Sponsor
- Sanofi
Peripheral Arterial Disease
BioMimics 3D Stent Clinical Investigation: The Mimics Study
Primary purpose of the Mimics Study is to evaluate the safety and performance of the BioMimics 3D Stent System in the treatment of symptomatic SFA/proximal popliteal disease.
- Trial name
- Mimics (NCT02163863)
- Testing
- Femoropopliteal stenting
- Where
- Germany
- Volunteers
- 86 people
- Sponsor
- Veryan Medical Ltd.
Stasis Dermatitis
Study Evaluating Efficacy and Safety of Crisaborole in Adults With Stasis Dermatitis
This is a Phase 2a, randomized, double blind, vehicle controlled, parallel group, proof of concept study that will include participants with stasis dermatitis without active skin ulceration, who will receive crisaborole ointment…
- Trial name
- NCT04091087
- Testing
- crisaborole ointment, vehicle ointment
- Where
- 4 sites in United States
- Volunteers
- 66 people
- Sponsor
- Pfizer
Essential Hypertension
Efficacy of Amlodipine-folic Acid Tablets on Reduction of Blood Pressure and Plasma Homocysteine
To evaluate the efficacy of Amlodipine-folic Acid Tablets on reduction of blood pressure and plasma homocystein.
- Trial name
- NCT01848873
- Testing
- Amlodipine, amlodipine-FA tablet, low dose group, amlodipine-FA tablet ,high dose group
- Where
- 16 sites in China
- Volunteers
- 756 people
- Sponsor
- Shenzhen Ausa Pharmed Co.,Ltd
Hypertriglyceridemia, Atherosclerotic Cardiovascular Disease
A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Adults With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease (Established or at Increased Risk for), and/or With Severe Hypertriglyceridemia
The purpose of the study was to evaluate the effect of olezarsen on percent change in fasting triglyceride (TG) levels compared to placebo at Months 6 and 12 and the proportion of participants who achieve different thresholds in…
- Conditions
- Hypertriglyceridemia, Atherosclerotic Cardiovascular Disease, Severe Hypertriglyceridemia
- Trial name
- NCT05355402
- Testing
- Olezarsen
- Where
- 24 sites in United States, Canada
- Volunteers
- 154 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Lupus Nephritis, Immunoglobulin A Nephropathy
An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular Diseases
The goal of this clinical study is to evaluate multiple dose levels of povetacicept in adults with immunoglobulin A (IgA) nephropathy (IgAN), primary membranous nephropathy (pMN), lupus-related kidney disease (lupus nephritis …
- Conditions
- Lupus Nephritis, Immunoglobulin A Nephropathy, Membranous Nephropathy, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
- Trial name
- RUBY-3 (NCT05732402)
- Testing
- Povetacicept
- Where
- 30 sites in United States, Australia and 2 more
- Volunteers
- 72 people
- Sponsor
- Alpine Immune Sciences, Inc.
Essential Hypertension
Efficacy and Safety of Valsartan/Amlodipine in Patients With Mild to Moderate Essential Hypertension
This study assessed the efficacy and safety of the valsartan/amlodipine 160/5 mg single-pill combination in patients with uncomplicated essential hypertension not adequately controlled (MSDBP ≥90 mmHg and <110 mmHg) on valsartan…
- Trial name
- NCT01001572
- Testing
- Valsartan/amlodipine 160/5 mg, Valsartan 160 mg
- Volunteers
- 932 people
- Sponsor
- Novartis
Bone Metastasis, Cancer Pain
Phase 3 Study on the Efficacy and Safety of Tanezumab in Patients With Cancer Pain Due to Bone Metastasis Who Are Taking Background Opioid Therapy
The purpose of this study is to determine whether tanezumab is effective in the treatment of cancer pain due to bone metastasis in patients already taking background opioid therapy.
- Trial name
- NCT02609828
- Testing
- Tanezumab
- Where
- 89 sites in Argentina, Australia and 14 more
- Volunteers
- 156 people
- Sponsor
- Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.